Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

Description

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

Conditions

Keratoconus, Corneal Ectasia

Talk to us

Study Overview

On this page

Study Details

Study overview

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

A Randomized Study to Evaluate the Safety and Efficacy of Corneal Collagen Crosslinking Performed With Continuous vs Pulsed UVA Light for Reducing Corneal Curvature in Eyes With Keratoconus and Post-refractive Corneal Ectasia

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

Condition
Keratoconus
Intervention / Treatment

-

Contacts and Locations

Teaneck

Cornea and Laser Eye Institute, Hersh Vision Group, Teaneck, New Jersey, United States, 07666

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years of age or older having a diagnosis of keratoconus or corneal ectasia after corneal refractive surgery
  • * Presence of central or inferior corneal steepening on the Pentacam map
  • * Axial topography consistent with keratoconus or post-surgical corneal ectasia
  • * Contact lens wearers only: removal of contact lenses for the required period of 1 week prior to the screening refraction
  • * Signed written informed consent
  • * Willingness and ability to comply with schedule for follow-up visits
  • * Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme
  • * Corneal pachymetry measuring 300 microns or less at the thinnest point measured by Pentacam in the eye(s) to be treated
  • * Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example:
  • 1. History of corneal disease (e.g. herpes simplex, herpes zoster keratitis, recurrent corneal erosion syndrome, corneal melt, corneal dystrophy, etc.
  • 2. Clinically significant scarring in the CXL treatment zone
  • * A history of chemical injury or delayed healing in the eye(s) to be treated
  • * Pregnancy (including plan to become pregnant) or lactation during the course of the study
  • * A known sensitivity to study medications
  • * Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests
  • * Patients with current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Cornea and Laser Eye Institute,

Peter S Hersh, MD, STUDY_DIRECTOR, Cornea and Laser Eye Institute, Hersh Vision Group

Study Record Dates

2025-07